PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Clevidipine Versus Nicardipine in Hypertensive Crisis: Three Studies, Very Low Certainty

clevidipinenicardipinedihydropyridine calcium channel blockerhypertensive crisishypertensive emergencyintravenous antihypertensivemeta-analysisblood pressure over-reductionGRADEcardiology Cardiology

Background Information

Clevidipine and nicardipine equally effective in hypertensive crises management.

Clevidipine and nicardipine are both used for hypertensive crises, yet their comparative efficacy and safety are not well established. Clevidipine had comparable efficacy to nicardipine in target blood pressure reduction with lower odds of over-reduction and less medication volume required. The findings suggest clevidipine may have advantages but are based on very low-certainty evidence, limiting their immediate applicability. Clevidipine and nicardipine show similar efficacy, clevidipine possibly safer in some respects, but evidence is weak.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Abid H, Shah SMA, Rashid AZ, Tasawar B, Adnan R, Memon S, Lohano G, Jawad M, Vazaym M, Junaid M

Citation: Abid H, Shah SMA, Rashid AZ, et al. Clevidipine vs. nicardipine in hypertensive crisis: a systematic review and meta-analysis. BMC cardiovascular disorders. 2026;26(1). doi:10.1186/s12872-026-06345-z

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.